EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arcus Biosciences's enterprise value is $-14.7 Mil.
Arcus Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-377.0 Mil. Therefore, Arcus Biosciences's EV-to-EBITDA for today is 0.04.
The historical rank and industry rank for Arcus Biosciences's EV-to-EBITDA or its related term are showing as below:
RCUS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.02 Med: -2.18 Max: 52.61
Current: 0.04
During the past 9 years, the highest EV-to-EBITDA of Arcus Biosciences was 52.61. The lowest was -16.02. And the median was -2.18.
RCUS's EV-to-EBITDA is ranked better than 95.77% of 496
companies
in the Biotechnology industry
Industry Median: 7.77
vs RCUS: 0.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Arcus Biosciences EV-to-EBITDA Historical Data
The historical data trend for Arcus Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arcus Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, Arcus Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's EV-to-EBITDA falls into.
Arcus Biosciences's current Enterprise Value is $-14.7 Mil.
Arcus Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-377.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arcus Biosciences's PE Ratio (TTM) for today is calculated as:
Arcus Biosciences's share price for today is $8.87.
Arcus Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Arcus Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCUS has been successfully added to your 